Skip to main content

Validation of a personalised medicine tool for Multiple Myeloma that predicts treatment effectiveness in patients

Objective

The consortium aims to commercialise the MMpredictor as a personalised medicine tool that predicts the most effective treatment strategy for individual Multiple Myeloma (MM) patients. MM is the second most common form of blood cancer contributing to 15% of all blood cancers and ~1,5% and 2% of all cancer deaths annually in the EU and US, respectively. Patients show a large variability in treatment response and side effects due to tumour heterogeneity and the patient’s intrinsic characteristics. Therefore, not every treatment will be suitable for each patient, and treatment strategies are often based on trial-and-error. The availability of multiple (>20) treatment options complicates treatment decision-making even more. With the current development of many more promising treatments, there is an urgent unmet clinical need for a diagnostic assay that supports personalised cancer treatment in order to improve patient health outcomes, prevent side effects and reduce healthcare costs.
SkylineDx has previously developed the MMprofiler, a microarray-based diagnostic test that can subtype MM patients and reliably predict MM patient survival (prognosis). In this project, the test’s clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling. An addendum for new intended use will be filed to the current in vitro diagnostic (IVD) registration, while renaming the test to MMpredictor. The project will also focus on positioning the test as a cost-effective IVD test for personalised medicine, that will increase health outcome and quality of life of patients and reduce healthcare costs.
The consortium consists of a life science SME specialised in molecular diagnostics, clinical centres with world renowned KOLs, a leading health economic institute, and a European MM patient advocacy organisation combining all the required complementary expertise to successfully bring the MMpredictor to market.

Coordinator

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Net EU contribution
€ 419 687,50
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Netherlands

See on map

Region
West-Nederland Zuid-Holland Groot-Rijnmond
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Participants (4)

UNIVERSITA DEGLI STUDI DI TORINO
Italy
Net EU contribution
€ 387 500,00
Address
Via Giuseppe Verdi 8
10124 Torino

See on map

Region
Nord-Ovest Piemonte Torino
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
SKYLINEDX B.V.
Netherlands
Net EU contribution
€ 1 882 475,00
Address
Lichtenauerlaan 40
3062 ME Rotterdam

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
West-Nederland Zuid-Holland Groot-Rijnmond
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 806 775,00
ERASMUS UNIVERSITEIT ROTTERDAM
Netherlands
Net EU contribution
€ 210 615,00
Address
Burgemeester Oudlaan 50
3062 PA Rotterdam

See on map

Region
West-Nederland Zuid-Holland Groot-Rijnmond
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
MYELOMA PATIENTS EUROPE AISBL
Belgium
Net EU contribution
€ 48 750,00
Address
Avenue Louise 143 4
1050 Bruxelles

See on map

Region
Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad
Activity type
Other
Non-EU contribution
€ 0,00